ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2015
The impact of thymoma histotype on prognosis in a worldwide database.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 2 syntheses or guidelines pooled it, 219 citations in OpenAlex.
- Risk factors for postoperative myasthenia gravis in patients with thymoma without myasthenia gravis: A systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Thymomas With Intravascular and Intracardiac Growth.Frontiers in oncology · 2022Pooled it
- Trial
- Article
- Survival and relapse of Danish patients with thymic epithelial tumors.Acta oncologica (Stockholm, Sweden) · 2026Article
- Long-Term Outcomes of Surgery for Thymic Epithelial Tumors With Pleural Metastases.JTO clinical and research reports · 2026Article
- Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy.Cancer immunology, immunotherapy : CII · 2026Review
- Integrative Multiomic Classification Reveals Distinct Origins and Evolutionary Trajectories of Thymic Epithelial Tumors.Cancer research · 2026Article
- A rare case of thymoma with extensive clear cell components: a discussion of its clear cell transformation.Medical molecular morphology · 2026Article
- Genome-wide analysis of somatic noncoding mutation patterns and mitochondrial heteroplasmic shift in type B1 and B2 thymomas.The Journal of pathology · 2026Article
- A Shift from Standard Median Sternotomy to Robotic-Assisted Thoracic Surgery for Resection of Anterior Mediastinal Tumors.Journal of clinical medicine · 2026Article
- Atypical type A thymoma: a narrative review of a distinct and progressive variant of low-risk thymoma.Mediastinum (Hong Kong, China) · 2026Review
- Solitary Hepatic Metastasis of Thymoma: A Case Report.Surgical case reports · 2026Article
- Recurrence and primary TETs: is it the same disease?-a narrative review.Mediastinum (Hong Kong, China) · 2026Review
- Contrast-enhanced CT-based habitat radiomics for distinguishing low-risk thymomas from high-risk thymomas: a multicenter study.Japanese journal of radiology · 2026Article
- Neoadjuvant Glucocorticoids Facilitate Resection in Advanced B-Type Thymomas: A Propensity-Matched Analysis of Surgical and Survival Outcomes.Thoracic cancer · 2026Article
- Narrative review: locally advanced thymoma-do we really need induction therapy before extended resection?Mediastinum (Hong Kong, China) · 2026Review
- Advanced Masaoka-Koga stage as an independent predictor of thymoma recurrence after complete resection: myasthenia gravis was not an independent factor.Gland surgery · 2025Article
- B2 Thymoma with Intracardiac Extension Presenting as Superior Vena Cava Syndrome: Case Report and Literature Review.Acta medica academica · 2025Review
- CD55 may be an important prognostic factor of thymic epithelial tumors: a retrospective study.World journal of surgical oncology · 2025Article
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 3 countries.
Funding
Abstract
introductionThe rarity of thymomas and lack of multi-institutional studies have hampered therapeutic progress for decades. To overcome this, the members of the International Thymic Malignancy Interest Group created a worldwide retrospective database. This database was analyzed regarding the demographic and geographic distribution of thymomas and the impact of different variables on survival and recurrence.
methodsThis study analyzed 4221 thymomas diagnosed between 1983 and 2012 with World Health Organization histotype information from the International Thymic Malignancy Interest Group database. Associations to survival and recurrence were studied by univariate and multivariate analyses.
resultsType B2 thymoma is the most common (28%) and type A the least common (12%) histotypes. They are significantly more frequent in Europe and the United States than Asia. Type A and AB occur at significantly higher age than other thymomas (64 and 57 years, respectively). There are no differences in gender distribution. Stage is lower in type A (90% in stages I-II) and AB than B1 to B3 thymomas (38% of type B3 in stage III). In univariate analysis, recurrence is significantly less frequent among stage I/II tumors, in type A and AB (recurrence rates, 1-2%) than B1 to B3 thymomas (2-7%). Multivariate analysis reveals an impact of age, stage, and resection status on survival and recurrence, whereas for histology there is only a significant impact on recurrence.
conclusionNew findings are (1) geographic differences such as a lower incidence of type A and B2 thymoma in Asia; and (2) impact of stage and histology, the latter partially limited to early stage disease, on recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.